Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 21
Tirzepatide and oral health questions
A new oral medicine letter raises an important question about tirzepatide, while the human evidence on oral-health outcomes remains limited.
Can peptides fix a slow metabolism?
A reader on r/peptides asked if peptides could fix years of unexplained weight gain. Here is what GLP-1 drugs actually do, and what to test first.
Can GLP-1 Drugs Help Ulcerative Colitis?
A matched cohort study links semaglutide and liraglutide use to higher ulcerative colitis remission, though neither drug is approved for IBD.
Old retatrutide pen: still safe to use?
Retatrutide is investigational, and even FDA-approved GLP-1 pens must be discarded weeks after first use, not months later.
Orzeyful isn't Ozempic for the brain
The FDA approved oveporexton for narcolepsy in August 2026. It targets the neuropeptide orexin, but the drug itself is not a peptide like semaglutide.
Retatrutide in 2026 Q2: what changed
Retatrutide closed its first Phase 3 obesity trial, published its first Phase 3 diabetes paper, and stayed unapproved in every market we cover.
Semaglutide in 2026 Q2: what changed
Semaglutide gained an oral tablet in Europe and the UK during Q2 2026, while the FDA moved to close the bulk route compounders rely on.
Combining Tesamorelin, Ipamorelin and TRT
A reddit user's heart rate spiked to 151 bpm after combining tesamorelin, ipamorelin and TRT. Here is what the evidence on each actually shows.
Tirzepatide and a rare skin rash: one case
A 2026 case report describes a chest rash clearing during tirzepatide-associated weight loss. Here is what one patient shows, and does not.
Tirzepatide and Prader-Willi diabetes
A 2026 case report describes tirzepatide easing treatment-resistant diabetes in an adult with Prader-Willi syndrome. Here is what one patient shows.
Why the 'Wolverine Stack' Didn't Work
BPC-157 and TB-500, the 'wolverine stack,' carry risks from unverified sourcing and peer-relayed dosing on top of thin human evidence.
CJC-1295 + ipamorelin + BPC-157 frequency
No validated injection schedule exists for CJC-1295, ipamorelin and BPC-157. Here is what published literature covers and where the gaps are.